440 related articles for article (PubMed ID: 15641865)
1. Effects of psychiatric disorders and psychotropic medications on prolactin and bone metabolism.
Misra M; Papakostas GI; Klibanski A
J Clin Psychiatry; 2004 Dec; 65(12):1607-18; quiz 1590, 1760-1. PubMed ID: 15641865
[TBL] [Abstract][Full Text] [Related]
2. [Guidelines for the prescription of mood stabilizers for adolescents: A literature review].
Munch G; Godart N
Encephale; 2017 Oct; 43(5):464-470. PubMed ID: 27871720
[TBL] [Abstract][Full Text] [Related]
3. Relationship between antipsychotic medication, serum prolactin levels and osteoporosis/osteoporotic fractures in patients with schizophrenia: a critical literature review.
De Hert M; Detraux J; Stubbs B
Expert Opin Drug Saf; 2016 Jun; 15(6):809-23. PubMed ID: 26986209
[TBL] [Abstract][Full Text] [Related]
4. Reduced bone mineral density in patients with schizophrenia receiving prolactin raising anti-psychotic medication.
Meaney AM; O'Keane V
J Psychopharmacol; 2003 Dec; 17(4):455-8. PubMed ID: 14870961
[TBL] [Abstract][Full Text] [Related]
5. Decreased bone mineral density in medicated psychiatric patients.
Halbreich U; Rojansky N; Palter S; Hreshchyshyn M; Kreeger J; Bakhai Y; Rosan R
Psychosom Med; 1995; 57(5):485-91. PubMed ID: 8552740
[TBL] [Abstract][Full Text] [Related]
6. [Plasma prolactin level and incidence of adverse endocrinologic effects during therapy with atypical neuroleptics].
Fric M; Laux G
Psychiatr Prax; 2003 May; 30 Suppl 2():S97-101. PubMed ID: 14509051
[TBL] [Abstract][Full Text] [Related]
7. Hyperprolactinemia associated with psychotropics--a review.
Madhusoodanan S; Parida S; Jimenez C
Hum Psychopharmacol; 2010; 25(4):281-97. PubMed ID: 20521318
[TBL] [Abstract][Full Text] [Related]
8. [Antipsychotic-drug-induced hyperprolactinemia: physiopathology, clinical features and guidance].
Besnard I; Auclair V; Callery G; Gabriel-Bordenave C; Roberge C
Encephale; 2014 Feb; 40(1):86-94. PubMed ID: 23928066
[TBL] [Abstract][Full Text] [Related]
9. Antipsychotic drugs: a new risk factor for osteoporosis in young women with schizophrenia?
O'Keane V; Meaney AM
J Clin Psychopharmacol; 2005 Feb; 25(1):26-31. PubMed ID: 15643097
[TBL] [Abstract][Full Text] [Related]
10. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment.
Montgomery J; Winterbottom E; Jessani M; Kohegyi E; Fulmer J; Seamonds B; Josiassen RC
J Clin Psychiatry; 2004 Nov; 65(11):1491-8. PubMed ID: 15554761
[TBL] [Abstract][Full Text] [Related]
11. Effects of elevated serum prolactin on bone mineral density and bone metabolism in female patients with schizophrenia: a prospective study.
Abraham G; Paing WW; Kaminski J; Joseph A; Kohegyi E; Josiassen RC
Am J Psychiatry; 2003 Sep; 160(9):1618-20. PubMed ID: 12944336
[TBL] [Abstract][Full Text] [Related]
12. Antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia.
O'Keane V
J Psychopharmacol; 2008 Mar; 22(2 Suppl):70-5. PubMed ID: 18477623
[TBL] [Abstract][Full Text] [Related]
13. Management of psychotropic-induced hyperprolactinemia.
Marken PA; Haykal RF; Fisher JN
Clin Pharm; 1992 Oct; 11(10):851-6. PubMed ID: 1341991
[TBL] [Abstract][Full Text] [Related]
14. Hyperprolactinemia and medications for bipolar disorder: systematic review of a neglected issue in clinical practice.
Pacchiarotti I; Murru A; Kotzalidis GD; Bonnin CM; Mazzarini L; Colom F; Vieta E
Eur Neuropsychopharmacol; 2015 Aug; 25(8):1045-59. PubMed ID: 25937241
[TBL] [Abstract][Full Text] [Related]
15. Clinical characteristics and length of hospital stay among older adults with bipolar disorder, schizophrenia or schizoaffective disorder, depression, and dementia.
Sajatovic M; Friedman SH; Sabharwal J; Bingham CR
J Geriatr Psychiatry Neurol; 2004 Mar; 17(1):3-8. PubMed ID: 15018690
[TBL] [Abstract][Full Text] [Related]
16. Risperidone-induced hyperprolactinemia in adolescents: A case series.
Madhusoodanan S; Moise D
J Clin Psychiatry; 2006 Jul; 67(7):1110-3. PubMed ID: 16889455
[TBL] [Abstract][Full Text] [Related]
17. Clinical questions and uncertainty--prolactin measurement in patients with schizophrenia and bipolar disorder.
Walters J; Jones I
J Psychopharmacol; 2008 Mar; 22(2 Suppl):82-9. PubMed ID: 18477624
[TBL] [Abstract][Full Text] [Related]
18. Antipsychotic-induced hyperprolactinemia inhibits the hypothalamo-pituitary-gonadal axis and reduces bone mineral density in male patients with schizophrenia.
Kishimoto T; Watanabe K; Shimada N; Makita K; Yagi G; Kashima H
J Clin Psychiatry; 2008 Mar; 69(3):385-91. PubMed ID: 18278991
[TBL] [Abstract][Full Text] [Related]
19. Targeting Hormones for Improving Cognition in Major Mood Disorders and Schizophrenia: Thyroid Hormones and Prolactin.
Tost M; Monreal JA; Armario A; Barbero JD; Cobo J; García-Rizo C; Bioque M; Usall J; Huerta-Ramos E; Soria V; ; Labad J
Clin Drug Investig; 2020 Jan; 40(1):1-14. PubMed ID: 31612424
[TBL] [Abstract][Full Text] [Related]
20. Use of mood stabilizers for hospitalized psychotic and bipolar disorder patients.
Ventriglio A; Vincenti A; Centorrino F; Talamo A; Fitzmaurice G; Baldessarini RJ
Int Clin Psychopharmacol; 2011 Mar; 26(2):88-95. PubMed ID: 21030870
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
